Vaxart (OTCMKTS:VXRT) Upgraded to “Hold” at Zacks Research

Vaxart (OTCMKTS:VXRT) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Vaxart Price Performance

Vaxart stock opened at $0.55 on Thursday. The company has a market capitalization of $132.59 million, a price-to-earnings ratio of 3.64 and a beta of 1.09. Vaxart has a one year low of $0.30 and a one year high of $0.84. The company’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.62.

Vaxart (OTCMKTS:VXRT) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%. As a group, sell-side analysts anticipate that Vaxart will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VXRT. Goldman Sachs Group Inc. bought a new position in Vaxart in the 1st quarter worth $31,000. Creative Planning bought a new position in shares of Vaxart in the second quarter worth about $33,000. Invesco Ltd. lifted its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. boosted its stake in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares during the period. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.